SBRT 2016

Progression under targeted systemic

Nivolumab in unselected patients

Gefitinib in mutant EGFR

Crizotinib in ALK positive

Maemondo NEJM 2010

Shaw NEJM 2013

Brahmer NEJM 2015

 Substantial and clinically relevant improvement  Still: 60 – 80% develop progressive disease after 12 months

ESTRO SBRT COURSE 2016 - Matthias Guckenberger

18

/